Subjects performed 9 wk of isokinetic knee extensions twice weekly. Albuterol (N = 13) or placebo (N = 9) was administered for 6 wk; groups received 16 mg · d-1 of either treatment. Training consisted of three sets of 10 repetitions at 45° · s-1. Data were collected at weeks 0, 6, and 9. Concentric and eccentric variables examined included: peak torque (CPT, EPT), total work (CTW, ETW), average power (CAP, EAP), time to peak torque (CTTPT, ETTPT), peak torque to body weight ratio (CPT/BW, EPT/BW), and work to body weight ratio (CW/BW, EW/BW). Other variables included: thigh circumference (CIRC), thigh cross-sectional area (CSA), forced vital capacity (FVC), and forced expiratory volume (FEV1). MANOVA and the Dunn-Bonferroni posthoc found differences within groups for CPT, CTW, CAP, CPT/BW, EPT, ETTPT, and CSA. Interactions were noted for CW/BW, ETW, EAP, EPT/BW, and ETW/BW; with persons administered albuterol yielding superior values. CW/BW, ETW, and EAP showed interactions at post-testing, while EPT/BW and EW/BW interacted at both midtesting and post-testing. Results indicate therapeutic doses of albuterol administered with resistance exercise may augment strength gains.
- β AGONIST
ASJC Scopus subject areas
- Public Health, Environmental and Occupational Health
- Physical Therapy, Sports Therapy and Rehabilitation
- Orthopedics and Sports Medicine